Effects of Medical Cannabis Market Size on Adolescents

Quarterly Insights from the RAND Drug Policy Research Center | View in browser

Join RAND on Facebook Follow RAND on Twitter

Quarterly insights from the RAND Drug Policy Research Center

December 2022

Cannabis green leaves in medical plus sign emblem frame on white background, photo by Amax Photo/Getty Images

Effects of Medical Cannabis Market Size on Adolescents

Combining a novel measure of market size with two shocks to U.S. federal enforcement policy, authors find that legal medical market growth increases youth cannabis use and alcohol-involved car accidents, suggesting complementarities for youths. It's unclear whether these results apply to cannabis legalization for nonmedical purposes. Read more »

Rosanna Smart, Co-director of the Drug Policy Research Center, photo by Diane Baldwin

Photo by Diane Baldwin/RAND Corporation

Congrats! Rosanna Smart Now Co-leading the DPRC

Rosanna Smart, a leading economist working on drug policy, is now co-leading the DPRC. She and Beau Kilmer co-direct the center, which remains committed to promoting healthier and more just societies throughout the world by improving knowledge and policy on alcohol and other drugs. Read More »

Emergency department signs, photo by pablohart/Getty Images

Photo by pablohart/Getty Images

The Impact of the Affordable Care Act Insurance Expansions on Opioid-Related Emergency Department Visits

Regardless of Medicaid expansion status, areas with higher uninsurance rates prior to the ACA saw larger reductions in opioid-related emergency department visits after the ACA took effect.

Read more »

Cannabis store sign on the street, photo by GoodLifeStudio/Getty Images

Photo by GoodLifeStudio/Getty Images

Cannabis Legalization in Europe: Planning Ahead

Since 2012, multiple jurisdictions have changed their laws to legalize the production, possession, and use of cannabis for nonmedical purposes. While most of these changes took place in the Americas, there are signs that the European legal landscape might be changing, too.

Read More »

Packages of Suboxone photographed in a pharmacy in Remington, Virginia, February 26, 2019, photo by Kris Tripplaar/Reuters

Photo by Kris Tripplaar/Reuters

Buprenorphine Use Remained Stable During First Year of Pandemic, but New Prescriptions Dropped During Period

The number of active prescriptions for the opioid disorder treatment drug buprenorphine remained constant during the first year of the COVID-19 pandemic, but the number of new prescriptions for the treatment was far below what would normally have been expected.

Read more »

Trending Research

Alcohol Use and Cannabis Use Trajectories and Sexual/Gender Minority Disparities in Young Adulthood

Buprenorphine Treatment Episode Duration, Dosage, and Concurrent Prescribing of Benzodiazepines and Opioid Analgesics: The Effects of Medicaid Prior Authorization Policies

DPRC in the News

Medication Treatment for Addiction Is Shorter for Black and Hispanic Patients, Study Finds

New York Times

Mushrooms, Slavery, and the Ballot Measures You May Have Missed

1A (NPR)

Gabapentin, Opioid Prescriptions More Likely to Overlap in Recent Years

Medpage Today

Contact

Rosanna Smart

Rosanna Smart

Co-Director, RAND Drug Policy Research Center

Economist

Beau Kilmer

Beau Kilmer

Co-Director, RAND Drug Policy Research Center

McCauley Chair in Drug Policy Innovation

Mafalda Pardal

Mafalda Pardal

RAND Europe Lead, RAND Drug Policy Research Center

Senior Analyst